Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (“EOC HK”) regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.
License Agreement Termination Summary
| Parameter | Detail |
|---|---|
| Original Agreement | April 2013 license between Syndax and EOC HK |
| Terminated Rights | Patents, intellectual property, and sub-licensing rights for entinostat |
| Chinese Approval | April 2024 for HR+/HER2- breast cancer (combination with aromatase inhibitors) |
| Sub-License Chain | EOC HK → Taizhou EOC (2018) → Suzhou Eddingpharm (2023) |
| Current Status | All license and sub-license agreements terminated |
| Commercial Impact | Immediate cessation of Jingzhuda commercialization rights in China |
Product Profile & Regulatory Status
- Drug Class: Oral histone deacetylase (HDAC) inhibitor
- Brand Name: Jingzhuda (China market)
- Indication: Hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer
- Patient Population: Patients who have relapsed or progressed on prior endocrine therapy
- Approval Date: April 2024 by Chinese regulatory authorities
- Therapeutic Significance: Addresses significant unmet need in endocrine-resistant breast cancer
Licensing Structure & Termination Cascade
Original 2013 Agreement
- Parties: Syndax Pharmaceuticals (licensor) and EOC HK (licensee)
- Rights Granted: Exclusive rights to relevant patents, intellectual property, and sub-licensing authority for entinostat
- Territory: Presumably included mainland China and potentially broader Asian markets
Sub-License Chain (2018-2023)
- 2018: EOC HK sub-licensed mainland China rights to Taizhou EOC Pharma Co., Ltd.
- 2023: Taizhou EOC further licensed Suzhou Eddingpharm Co., Ltd. for commercialization of entinostat in human cancers and companion diagnostic testing
Termination Impact
- EOC HK: No longer holds any rights to entinostat
- Taizhou EOC: Sub-license automatically terminated due to upstream termination
- Suzhou Eddingpharm: Commercialization rights revoked, halting marketing activities
- Market Access: Immediate disruption to Jingzhuda availability for Chinese patients
Strategic Implications
For Syndax Pharmaceuticals
- Direct Control: Regains full control over entinostat commercialization strategy in China
- Alternative Partnerships: May seek new commercial partner with stronger execution capabilities
- Revenue Impact: Loss of royalty stream from existing commercialization, but potential for improved terms with new partner
- Strategic Reassessment: Opportunity to restructure China strategy following recent approval
For Chinese Pharmaceutical Companies
- EOC HK/Taizhou EOC: Significant setback to oncology portfolio and revenue expectations
- Suzhou Eddingpharm: Loss of recently launched commercial product and associated investment
- Market Disruption: Chinese patients may face temporary access issues for approved indication
For Chinese Breast Cancer Market
- Treatment Continuity: Potential interruption in access to approved HDAC inhibitor combination therapy
- Competitive Landscape: Creates opportunity for alternative HDAC inhibitors or competing mechanisms
- Regulatory Precedent: Highlights risks of complex multi-tier licensing structures in Chinese pharmaceutical market
The termination represents a significant disruption to the commercial ecosystem established for entinostat in China and underscores the complexities of international pharmaceutical licensing in emerging markets.
Forward‑Looking Statements
This brief contains forward-looking statements regarding business relationships, commercial strategies, and market impacts. Actual outcomes may differ materially due to regulatory decisions, competitive dynamics, patient access considerations, and strategic realignments by involved parties.-Fineline Info & Tech
